Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2001-02-01
2003-03-25
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S570000, C514S557000, C514S012200, C514S008100, C514S04400A, C514S021800, C514S567000
Reexamination Certificate
active
06538028
ABSTRACT:
TECHNICAL FIELD
The present invention pertains generally to modulation of activation of the complement system. More particularly, the present invention pertains to the inhibition of complement activation through the inhibition of platelet receptors for thrombin/fibrinogen. In a preferred embodiment, the present invention pertains to a method of inhibiting of transplant rejection by blocking complement activation in a recipient.
Table of Abbreviations
ATA
aurintricarboxylic acid
C
complement, usually followed by a number
from 1 to 9 when referencing the factors of
the complement system in the immune
system
C3a
complement activation factor
C5b-9
complement activation factors
CDR
complementarity determining region
CVF
cobra venom factor
Fg
fibrinogen
Fn
fibronectin
GPlb
platelet receptor involved in platelet
activation and aggregation
GPllb/llla
platelet receptor involved in platelet
activation and aggregation
HAR
hyperacute rejection
HCl
hydrochloric acid
PPP
platelet poor plasma
PRP
platelet rich plasma
PVR
pulmonary vascular resistance
SC52012A
selective potent GPllb/llla antagonist
TFA
trifluoroacetic acid
TXA2
thromboxane
vWF
von Willebrand's Factor
BACKGROUND ART
The complement system is a complex interaction of plasma proteins and membrane cofactors which act in a multi-step, multi-protein cascade sequence in conjunction with other immunological systems of the body to provide immunity from intrusion of foreign cells. Complement proteins represent up to about 10% of globulins in normal serum of man and other vertebrate's. The term “complement” refers to the non-specific defense system that is activated by the bonding of antibodies to antigens and by this event is directed against specific invaders that have been identified by antibodies.
Organ procurement currently poses one of the major problems in organ transplantation, as the number of patients requiring transplants far exceeds the number of organs available. Moreover, a transplanted organ is often rejected by the recipient's body. Thus, even when an organ is available, transplant rejection presents a continuing problem.
Xenotransplantation may provide a solution to the shortage of organs for transplant. Phylogenetically, non-human primates are the most closely related species to humans and might therefore represent the first choice as donors. In 1969, Reetsma et al. achieved the first successful kidney human xenograft from a chimpanzee (Reetsma, K., et al., 1964
, Ann. Surg
. 160:384). However, the potential utilization of primate donors is limited by insufficient numbers, legal and ethical considerations, and the potential for transmitting dangerous viral diseases. Swine represent one of the few large animal species in which breeding characteristics make genetic experiments possible, making it possible to develop MHC homozygous lines of miniature swine, for example. Miniature swine can be maintained at maximum adult weights of 200 to 300 lbs and are anatomically and physiologically close to humans. Therefore, the organs of miniature swine seem appropriate for use as xenografts for human beings of all ages.
However, problems associated with transplant rejection also persist with respect to xenograft organs from swine and from other donors. Therefore, there remains a continuing and long-felt need for therapeutic methods that inhibit transplant rejection and that faciliate the use of xenograftt organs in transplant procedures.
SUMMARY OF THE INVENTION
A method of modulating complement activation in a warm-blooded vertebrate is disclosed. The method comprises administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate, whereby complement activation is modulated. The platelet activity modulator preferably comprises a combination of a GPIb modulator and a GPIIb/GPIIIa modulator.
A method of inhibiting complement activation by a transplanted tissue in a warm-blooded vertebrate is also disclosed. The method comprises administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby complement activation, by the transplanted tissue is inhibited. The platelet activity modulator preferably comprises a combination of a GPIb modulator and a GPIIb/GPIIIa modulator.
The therapeutically effective amount of the platelet activity modulator ranges from about 0.01 mg to about 10,000 mg per day, preferably from about 0.1 mg to about 1,000 mg per day, and more preferably from about 1 mg to about 300 mg per day.
The transplanted tissue can be a vascularized tissue. The vascularized tissue can include, but is not limited to heart, lung, liver, kidney, pancreas and combinations thereof.
The transplanted tissue can be xenograft tissue. The xenograft tissue can be vascularized xenograft tissue. The vascularized xenograft tissue can include, but is not limited to, heart, lung, liver, kidney, pancreas and combinations thereof. Optionally, the xenograft tissue is obtained from a donor animal having a deficient platelet activity pathway.
A method of inhibiting rejection of a transplanted tissue in a warm-blooded vertebrate is also disclosed. The method comprises administering a therapeutically effective amount of a GPIb modulator and a GPIIb/GPIIIa modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby rejection of the transplanted tissue is inhibited.
A method of enhancing tolerance of a xenograft transplant in a recipient is also disclosed. The method comprises administering a therapeutically effective amount of a GPIb modulator and a GPIIb/GPIIIa modulator to a recipient before, during or after the recipient receives a xenograft transplant, whereby tolerance of the xenograft transplant is enhanced.
Accordingly, it is an object of the present invention to provide a novel method for inhibiting transplant rejection. This and other objects are achieved in whole or in part by the present invention.
An object of the invention having been stated hereinabove, other objects will become evident as the description proceeds when taken in connection with the accompanying Drawings and Laboratory Examples as best described hereinbelow.
REFERENCES:
patent: 4007270 (1977-02-01), Bernstein et al.
patent: 4880788 (1989-11-01), Moake et al.
patent: 5135916 (1992-08-01), Sims et al.
patent: 5434185 (1995-07-01), Collings et al.
patent: 5550108 (1996-08-01), Sims et al.
patent: 5573940 (1996-11-01), Sims et al.
patent: 5635178 (1997-06-01), Sims et al.
patent: 5660825 (1997-08-01), Sims et al.
patent: 5679345 (1997-10-01), Sanfilippo et al.
patent: 5763156 (1998-06-01), Sims et al.
patent: 5858963 (1999-01-01), Hawley et al.
patent: 5891645 (1999-04-01), Rollins et al.
patent: 5955441 (1999-09-01), Sims et al.
patent: 43 38 793 (1995-05-01), None
patent: 0 251 134 (1988-07-01), None
patent: 07196650 (1995-08-01), None
Ekre, Hans-Peter, “Inhibition of Human and Guinea Pig Complement by Heparin Fractions Differing in Affinity for Antithrombin III or in Average Molecular Weight,” International Journal of Immunopharmacology (Elmsford, NY, US), vol. 7 (No. 2),p. 271-275, ( Sep. 21, 1984).
Bach, et al., “Delayed xenograft rejection,” Immunol. Today, Elsevier Publications (Cambridge, GB), vol. 17 ( No. 8), p. 379-384, ( Aug. 1, 1996).
Dorling, et al., “Clinical xenotransplantation of solid organs,” The Lancet, p. 867-871, ( Mar. 22, 1997).
Hoelschermann, et al., “Evaluation of Recombinant Hirudin in the Prevention of Experimental Cardiac Transplant Vasculopathy,” ( Nov. 2, 1999).
“The effects of cyclosporin A, ticlopidine hydrochloride and cobra venom factor on the hyperacute rejection of disocrodant renal xenografts”, Green et al, 1980, Investigative and Cell Pathology, 3(4), 415-416.*
“Platelet Thrombus Formation on injured Endothelial Cell Monolayers”, Nollert et al., www.aiche.org, 1999.*
“Cardiovascular Pharmacotherapy in Patients following Myocardial Infarction-the Role of Anti-platelet Agents, Ant
Azimzadeh Agnes M.
Giorgio Todd D.
Pierson, III Richard N.
Robson Simon
Zorn, III George L.
Fay Zohreh
Jenkins & Wilson, P.A.
Kwon Brian-Yong S.
Vanderbilt University
LandOfFree
Method for inhibiting complement activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting complement activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting complement activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3055757